- Home
- USEA vs NNVC Comparison
USEA vs NNVC Comparison
Compare USEA & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | NNVC |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 21.2M |
| IPO Year | 2022 | 2008 |
Fundamental Metrics
Financial Performance| Metric | USEA | NNVC |
|---|---|---|
| Price | $2.61 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.4K | ★ 958.3K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.85 |
| 52 Week High | $2.75 | $2.23 |
Technical Indicators
Market Signals| Indicator | USEA | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 46.67 |
| Support Level | $1.62 | $1.35 |
| Resistance Level | N/A | $1.48 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 62.90 | 34.88 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.